Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
复制标题
嵌合抗原受体(CAR)-T细胞免疫疗法治疗胸部恶性肿瘤：挑战和机遇。
DOI：
10.3389/fimmu.2022.871661
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
与手术、化疗、放疗和靶向治疗不同，CAR-T细胞是一种新型的过继免疫治疗策略，已成功用于血液肿瘤和实体肿瘤的治疗。尽管缺乏特异性抗原、肿瘤微环境免疫抑制、CAR-T细胞浸润肿瘤组织水平低、脱靶毒性等安全性问题降低了工程CAR-T细胞治疗胸部恶性肿瘤的临床试验效果，但CAR-T细胞治疗仍然充满光明的前景。本文综述了不同时期CAR-T细胞的基本结构和特征，总结了CAR-T细胞治疗胸部恶性肿瘤临床试验中常见的肿瘤相关抗原，并指出当前面临的挑战和新的策略，旨在为CAR-T细胞治疗胸部恶性肿瘤的临床前实验和临床试验提供新的思路和途径。
Different from surgery, chemical therapy, radio-therapy and target therapy, Chimeric antigen receptor-modified T (CAR-T) cells, a novel adoptive immunotherapy strategy, have been used successfully against both hematological tumors and solid tumors. Although several problems have reduced engineered CAR-T cell therapeutic outcomes in clinical trials for the treatment of thoracic malignancies, including the lack of specific antigens, an immunosuppressive tumor microenvironment, a low level of CAR-T cell infiltration into tumor tissues, off-target toxicity, and other safety issues, CAR-T cell treatment is still full of bright future. In this review, we outline the basic structure and characteristics of CAR-T cells among different period, summarize the common tumor-associated antigens in clinical trials of CAR-T cell therapy for thoracic malignancies, and point out the current challenges and new strategies, aiming to provide new ideas and approaches for preclinical experiments and clinical trials of CAR-T cell therapy for thoracic malignancies.
登录
查看更多内容
影响因子：
--
作者：
Li Y;Sui Y;Chi M;Zhang J;Guo L
通讯作者：
Guo L
影响因子：
46.9
作者：
Choi, Bryan D.;Yu, Xiaoling;Maus, Marcela V.
通讯作者：
Maus, Marcela V.
DOI：
10.1038/mto.2016.11
发表时间：
2016
期刊：
Molecular therapy oncolytics
影响因子：
--
作者：
通讯作者：
--
影响因子：
5.8
作者：
Ebert LM;Yu W;Gargett T;Toubia J;Kollis PM;Tea MN;Ebert BW;Bardy C;van den Hurk M;Bonder CS;Manavis J;Ensbey KS;Oksdath Mansilla M;Scheer KG;Perrin SL;Ormsby RJ;Poonnoose S;Koszyca B;Pitson SM;Day BW;Gomez GA;Brown MP
通讯作者：
Brown MP
影响因子：
10.8
作者：
Alibolandi, Mona;Ramezani, Mohammad;Hadizadeh, Farzin
通讯作者：
Hadizadeh, Farzin